Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

Abstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts...

Full description

Saved in:
Bibliographic Details
Main Authors: Marina G. Birck, Jessica Boivin, Laura Yan, Nathalie Carrier, Cristiano S. Moura, Walter P. Maksymowych, Gilles Boire, Denis Choquette, Luck Lukusa, Michael Mallinson, Linda Wilhelm, Autumn Neville, Sasha Bernatsky
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Etanercept
Remission induction
Biosimilar pharmaceuticals
Online Access:https://doi.org/10.1186/s13075-025-03607-7
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts who initiated ETA-B or ETA-O (Jan/2015-May/2022). Disease remission was determined using disease activity scales. Sustained remission was defined as at least two consecutive visits in remission within the first 12 months of follow-up. Multivariate Cox regression was used to compare the probability of achieving remission between ETA-B and ETA-O, and multivariate logistic regression was used to assess sustained remission. Results We studied 150 participants with RA (ETA-B: 65.3%). Among 125 participants not in remission at baseline, the median time to first remission was 8.7 months (95% confidence intervals [CI] 5.2–12.1) in the ETA-B group and 14.5 months (95% CI 4.7–18.6) in the ETA-O group. Time to first remission was similar between the groups (log-rank test: P-value = 0.51). Multivariate Cox regression showed no clear difference in first remission between ETA-B and ETA-O (adjusted hazard ratio 1.52, 95% CI 0.68–3.39). Among 125 participants with at least 12 months of follow-up, the prevalence of sustained remission was 19.5% for ETA-B and 21.0% for ETA-O. In multivariate analysis, we did not detect a significant difference in sustained remission between ETA-B and ETA-O (adjusted odds ratio 1.14, 95% CI 0.29–4.87). Conclusion We did not detect clear differences in first remission and sustained remission between participants with RA initiating ETA-B or ETA-O. Trial registration Not applicable.
ISSN:1478-6362

Similar Items